KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationInvestment in Debt & EquityLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Inovio Pharmaceuticals (INO) Other Gross PP&E Adjustments (2016 - 2026)

Inovio Pharmaceuticals' Other Gross PP&E Adjustments history spans 15 years, with the latest figure at $10.9 million for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 21.93% to $10.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.9 million, a 21.93% increase, with the full-year FY2025 number at $10.9 million, up 21.93% from a year prior.
  • Other Gross PP&E Adjustments hit $10.9 million in Q4 2025 for Inovio Pharmaceuticals, up from -$7.0 million in the prior quarter.
  • Over the last five years, Other Gross PP&E Adjustments for INO hit a ceiling of $21.2 million in Q4 2021 and a floor of -$12.8 million in Q1 2021.
  • Historically, Other Gross PP&E Adjustments has averaged -$4.0 million across 5 years, with a median of -$9.0 million in 2023.
  • Biggest five-year swings in Other Gross PP&E Adjustments: skyrocketed 87.12% in 2021 and later dropped 29.2% in 2024.
  • Tracing INO's Other Gross PP&E Adjustments over 5 years: stood at $21.2 million in 2021, then dropped by 28.78% to $15.1 million in 2022, then dropped by 16.4% to $12.6 million in 2023, then fell by 29.2% to $8.9 million in 2024, then rose by 21.93% to $10.9 million in 2025.
  • Business Quant data shows Other Gross PP&E Adjustments for INO at $10.9 million in Q4 2025, -$7.0 million in Q3 2025, and -$7.4 million in Q2 2025.